E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Non-Hodgkins Lymphoma
Chronic Lymphocytic Leukemia |
|
E.1.1.1 | Medical condition in easily understood language |
Non-Hodgkins Lymphoma
Chronic Lymphocytic Leukemia |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008976 |
E.1.2 | Term | Chronic lymphocytic leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 22.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029547 |
E.1.2 | Term | Non-Hodgkin's lymphoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To characterize safety, tolerability, and maximum tolerated dose/recommended dose for expansion of JBH492 single agent in patients with CLL and NHL |
|
E.2.2 | Secondary objectives of the trial |
-To evaluate the preliminary anti-tumor activity of single agent JBH492 in CLL -To evaluate the preliminary anti-tumor activity of single agent JBH492 in NHL -To determine the pharmacokinetics (PK) of single agent JBH492, including total antibody, total ADC, DM4, and sDM4 -To assess the immunogenicity (IG) of JBH492 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
For patients with CLL: • Confirmed diagnosis of chronic lymphocytic leukemia (CLL)
For patients with NHL: •Histologically confirmed diagnosis of B- or T-cell non-Hodgkins lymphoma (NHL). •Must have a site of disease amenable to biopsy, and be suitable and willing to undergo study required biopsies at screening and during therapy. Other inclusion criteria may apply.
|
|
E.4 | Principal exclusion criteria |
Applicable to both CLL and NHL: •History of anaphylactic or other severe hypersensitivity/infusion reactions to ADCs, monoclonal antibodies (mAbs) and/or their excipients such that the patient in unable to tolerate immunoglobulin/monoclonal antibody administration •Any prior history of treatment with maytansine (DM1 or DM4)-based ADC •Known intolerance to a maytansinoid •Patients with any active or chronic corneal disorders •Patients who have any other condition that precludes monitoring of the retina or fundus •Patients with active CNS involvement are excluded, except if the CNS involvement has been effectively treated and provided that local treatment was completed > 4 weeks before first dose of study treatment. Patients that have been effectively treated for CNS disease and are stable under systemic therapy may be enrolled provided all other inclusion and exclusion criteria are met. Patients who received prophylactic intrathecal treatment are eligible, if treatment discontinued >5 half-lives prior to the first dose of study treatment. •Impaired cardiac function or clinically significant cardiac disease •Known history of Human Immunodeficiency Virus (HIV) infection •Active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection Other exclusion criteria may apply. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety: Incidence and severity of dose limiting toxicities (DLTs), AEs and SAEs, including changes in laboratory values, vital signs and ECGs Incidence and nature of DLTs during the first treatment cycle (dose escalation only) Tolerability: Frequency of dose interruptions, reductions, dose intensity and dose intensity rate |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Overall response rate (ORR) per iwCLL response criteria, Best overall response (BOR), DOR, i.e. the time from achievement of CR/PR to first documented disease progression or death due to CLL, Progression-freesurvival (PFS) - Overall response rate (ORR) per Lugano criteria. Best overall response (BOR), DOR, i.e. the time from achievement of CR/PR or to first documented disease progression or death due to NHL, Progression-freesurvival (PFS) - PK parameters (e.g. AUC, Cmax, Cmin, Tmax, half-life) for four analytes (total Ab, total ADC, DM4, and sDM4); concentration vs. time profiles of four analytes - Incidence of anti-JBH492 antibodies |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Israel |
Japan |
Korea, Republic of |
Singapore |
United States |
Finland |
Spain |
Germany |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
- 80% of the subjects per disease group in the expansion part have completed the follow-up for disease progression or discontinued the study for any reason, all subjects have completed treatment and the 150 days safety follow-up for JBH492 single agent. - When the treatment period and the safety follow-up have been completed for all subjects in case that the disease follow-up evaluations might not be completed (in case that Novartis decides to stop enrollment prematurely). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 8 |